Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Pharmaceuticals Inc.

Executive Summary

Recently-established subsidiary will have direct responsibility for registration and marketing of Novo Nordisk drug products in the U.S. The two Danish firms Novo and Nordisk merged in 1989. The NNPI detail force of 150 reps will continue to perform the marketing activities previously conducted by Squibb-Novo, a joint venture set up in 1982 to handle the sales of Novo's insulin in the U.S. Squibb will continue to store and distribute orders for all Novo Nordisk diabetes care products, while the SquibbMark unit will provide merchandising support.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel